Science
Guilherme Nader Marta: Can SBRT Convert ‘Cold’ ER+/HER2− Breast Tumors into Immune-Responsive States?
Guilherme Nader Marta/X

Guilherme Nader Marta: Can SBRT Convert ‘Cold’ ER+/HER2− Breast Tumors into Immune-Responsive States?

Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Excited to see our Neo-CheckRay trial published in Nature Medicine.
Proud to have contributed to this multidisciplinary trial exploring whether XRT can help convert immunologically ‘cold’ tumors into a more immune-responsive state in high-risk ER+/HER2− early BC.”

Title: Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial

Authors: Alex De Caluwé, Isabelle Desmoulins, Kim Cao, Vincent Remouchamps, Adinda Baten, Eleonore Longton, Karine Peignaux, Andrea Joaquin Garcia, David Venet, Luca Arecco, Elisa Agostinetto, Guilherme Nader-Marta, Zoë Denis, Jennifer Dhont, Paulus Kristanto, Xavier Catteau, Denis Larsimont, Roberto Salgado, Philip Poortmans, John Stagg, Christos Sotiriou, Martine Piccart, Michail Ignatiadis, Emanuela Romano, Laurence Buisseret

Read the Full Article.

Guilherme Nader Marta: Can SBRT Convert 'Cold' ER+/HER2− Breast Tumors into Immune-Responsive States?

Other articles about breast cancer on OncoDaily.

Adinda Baten Alex De Caluwe Andrea Joaquín García Breast Cancer Christos Sotiriou David Venet Denis Larsimont Eleonore Longton Elisa Agostinetto Emanuela Romano Guilherme Nader Marta Isabelle Desmoulins Jennifer Dhont John Stagg Karine Peignaux Kim Cao Laurence Buisseret Luca Arecco Martine Piccart Michail ignatiadis Nature Medicine Paulus Kristanto Philip Poortmans Roberto Salgado Vincent Remouchamps Xavier Catteau Zoë Denis